AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) is a synthetic cannabinoid receptor agonist belonging to the indazolecarboxamide chemical class. Originally developed by Pfizer in 2009 during cannabinoid receptor research, it was subsequently identified in herbal smoking mixtures and the illicit synthetic cannabinoid market beginning around 2012. AB-FUBINACA is a full agonist at both CB1 and CB2 cannabinoid receptors — a pharmacological distinction from THC's partial agonism that underpins its dramatically greater potency and toxicity profile.
Synthetic cannabinoids as a class represent among the most dangerous substances in the novel psychoactive substance landscape. Full CB1 agonism produces effects qualitatively unlike cannabis at equipotent doses: cardiovascular toxicity (tachycardia, bradycardia, chest pain, myocardial infarction), seizures, renal failure, acute psychosis, and deaths have all been documented. AB-FUBINACA specifically has been associated with multiple mass poisoning events, clustered hospitalization incidents, and fatalities. Its appearance in products marketed as "herbal incense," "spice," or "K2" means users frequently have no knowledge of its identity or dose.
Safety at a Glance
High Risk- Primary Recommendation: Avoid
- Never use alone — have someone present who knows what you have taken
- Toxicity: Life-Threatening Toxicity AB-FUBINACA and other indazolecarboxamide synthetic cannabinoids have caused confirmed fata...
- Overdose risk: overdose will cause physical discomfort including heart palpitations, vertigo and sedation at muc...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
smoked
Duration
smoked
Total: 1 hrs – 2 hrsHow It Feels
AB-FUBINACA is one of the more potent synthetic cannabinoids, and its effects arrive with a force that can overwhelm even experienced cannabis users. Within moments of inhalation, a massive wave of sedation crashes through the body, pressing consciousness downward with an almost violent urgency. The transition from sober to profoundly altered happens so quickly that there is barely time to register the onset before the peak is already upon you. The eyes close involuntarily. The body goes slack.
The peak is dominated by an overwhelming sedation that goes far beyond the relaxed drowsiness of natural cannabis. This is not relaxation -- it is suppression, a pharmacological pressing-down of neural activity that leaves the mind functioning at a fraction of its normal capacity. Thoughts become sparse, separated by vast intervals of blankness. When they do appear, they are disjointed and hard to hold, slipping away like water through fingers. The emotional landscape is flat, evacuated of both anxiety and pleasure, leaving only a neutral warmth that lacks the richness and texture of natural cannabinoid experiences.
The body becomes extraordinarily heavy. Movement requires a deliberate effort that seems disproportionate to the task. Muscle coordination degrades sharply -- hands fumble, steps become uncertain, and the disconnect between the brain's commands and the body's execution widens into something almost comical if it were not also alarming. The heart rate increases significantly, sometimes dramatically, pounding in the chest with a force that can provoke anxiety even through the sedative fog. Nausea may surface, a queasy rolling in the stomach that threatens but does not always result in vomiting.
Visual and auditory perception are altered in ways that share some characteristics with cannabis but are amplified to uncomfortable extremes. Colors may appear oversaturated. Sounds echo or distort. There can be a sense of the visual field narrowing, tunnel vision closing in at the periphery, accompanied by a pressure behind the eyes that feels distinctly synthetic. Time distortion is profound and disorienting, each minute expanding to feel like many, the clock frozen in place.
The duration of intense effects is relatively short -- one to two hours -- but the comedown is rarely clean. As the peak subsides, it often leaves behind a persistent drowsiness, a headache, and a general sense of physical malaise that can last for hours. The appetite, suppressed during the peak by nausea, may rebound dramatically. Sleep comes easily but is often shallow and unrewarding, and the morning after carries a foggy, depleted quality that natural cannabis hangovers rarely match.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(14)
- Appetite enhancement— A distinct increase in hunger and desire for food, often accompanied by enhanced enjoyment of taste ...
- Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Cognitive & Perceptual Effects
Visual(4)
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Peripheral vision changes— Alterations in side vision ranging from enhanced peripheral awareness to tunnel vision, with charact...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Visual haze— A translucent fog or haze overlays the visual field, softening the environment and reducing clarity....
Cognitive(13)
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Dream suppression— Dream suppression is a decrease in the intensity, frequency, and recollection of dreams — ranging fr...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Auditory(3)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Pharmacology
Mechanism of Action: Full vs. Partial CB1 Agonism
The fundamental pharmacological distinction between synthetic cannabinoids like AB-FUBINACA and THC is efficacy at the CB1 receptor. THC is a partial agonist — it binds CB1 but produces only partial receptor activation, providing an intrinsic ceiling on its maximum physiological effect. AB-FUBINACA and most synthetic cannabinoids arefull agonists — producing maximal receptor activation regardless of dose.
This distinction has profound safety implications: the dose-response curve for a full agonist is steeper, the maximum effect size is larger, and there is no pharmacological ceiling to protect against excessive dosing. Effects that would require impossibly large THC doses are routinely reached with synthetic cannabinoids, explaining the cardiovascular and neurological toxicity absent from cannabis use.
Receptor Profile
AB-FUBINACA acts as a potent full agonist at both CB1 (psychoactive, cardiovascular, neurological effects) andCB2 (immune modulation) receptors. CB1 activation in the brain, heart, peripheral vasculature, and kidneys mediates the majority of toxic manifestations.
Potency
AB-FUBINACA is substantially more potent than THC on a mass basis — binding studies suggest potency exceeding THC by orders of magnitude at CB1. This means that the effective dose is in the microgram range, and the amounts sprayed onto herbal plant material in commercial products are highly uneven, creating hot spots that deliver many times the intended dose in a single inhalation.
Detection Methods
Standard Drug Panel Inclusion
AB-FUBINACA is a synthetic cannabinoid receptor agonist that is not detected on standard 5-panel drug screens. Standard THC immunoassays target 11-nor-9-carboxy-THC (THC-COOH), the primary metabolite of delta-9-THC, and do not cross-react with synthetic cannabinoids. Some expanded drug panels (12-panel or custom panels) include a synthetic cannabinoid channel, but coverage of specific compounds varies widely between manufacturers.
Urine Detection
AB-FUBINACA and its metabolites can be detected in urine for approximately 2 to 5 days after a single use, though chronic heavy use can extend this window to 7 or more days. Synthetic cannabinoids undergo extensive hepatic metabolism, primarily via hydroxylation and carboxylation, producing metabolites that are excreted in urine as glucuronide conjugates. The specific metabolite profile varies by compound and is a key factor in whether a given immunoassay can detect AB-FUBINACA.
Blood and Saliva Detection
Blood concentrations of AB-FUBINACA decline rapidly after use, with a detection window of approximately 12 to 48 hours for the parent compound. Metabolites may persist longer. Oral fluid testing can detect parent compound and early metabolites for approximately 24 to 48 hours, and some roadside testing devices include synthetic cannabinoid panels.
Hair Follicle Detection
Hair follicle analysis can detect synthetic cannabinoids for up to 90 days. However, incorporation rates and detectability vary by compound. Some laboratories offer expanded hair panels that include common synthetic cannabinoids such as JWH-018 and AB-FUBINACA metabolites, but coverage of newer compounds including AB-FUBINACA may be limited.
Confirmatory Testing
LC-MS/MS is the preferred confirmatory method for synthetic cannabinoids. The structural diversity and rapid evolution of this substance class means that reference standards must be available for the specific compound under investigation. GC-MS can also be used but LC-MS/MS offers superior sensitivity and specificity for the typically low concentrations encountered. Both parent compound and key metabolites should be targeted.
Reagent Testing
Standard reagent tests (Marquis, Mecke, Mandelin) are generally uninformative for synthetic cannabinoids, as these compounds are typically applied to herbal material at very low concentrations and produce no characteristic color reactions. Visual inspection and reagent testing cannot distinguish treated herbal material from untreated plant matter. Immunoassay-based test strips specific to synthetic cannabinoids are available from some harm reduction suppliers and represent a more practical point-of-use screening option.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,3-Butanediol | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 25E-NBOH | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-2 | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-21 | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 25x-NBOMe | Uncertain | — |
| 2C-T-x | Uncertain | — |
| 2C-x | Uncertain | — |
| Cocaine | Uncertain | — |
| DMT | Uncertain | — |
History
Pfizer Origins
AB-FUBINACA was originally synthesized by Pfizer researchers in 2009 as part of a systematic program to develop novel cannabinoid receptor ligands for pharmaceutical research. It was patented but never approved as a medication. Like several other potent synthetic cannabinoids (including JWH-018 and AM-2201), its synthesis was documented in academic and patent literature before being identified in recreational products.
Entry Into Illicit Markets
AB-FUBINACA first appeared in herbal smoking products in Japan in 2012, where synthetic cannabinoid products were initially marketed as "legal" alternatives to cannabis. It rapidly spread through European and North American markets, appearing in products labeled "Spice," "K2," and hundreds of brand names.
Regulatory Response
The United States DEA emergency-scheduled AB-FUBINACA as a Schedule I controlled substance in 2014. Most European nations followed with equivalent controls. Despite this, it remains available through illicit channels and is one of several dozen synthetic cannabinoids that cycle through the market as each generation is scheduled and replaced.
Harm Reduction
Primary Recommendation: Avoid
The harm-reduction consensus regarding AB-FUBINACA and potent synthetic cannabinoids is that no use pattern eliminates the life-threatening risk. The uneven distribution of active compound on herbal carrier material, the lack of reliable dose information, and the steep dose-response curve of full CB1 agonism means that even experienced users cannot reliably predict or control their dose.
If Use Occurs
- Never use alone — have someone present who knows what you have taken
- Start with a minimal inhalation — take a single small puff, wait 15–20 minutes before any further use; the fast onset from inhalation allows assessment before additional dosing
- Do not mix with other depressants, alcohol, benzodiazepines, or opioids — combined CNS depression and cardiovascular suppression dramatically amplifies toxicity
- Do not use with stimulants — combined cardiovascular strain (stimulant tachycardia + synthetic cannabinoid arrhythmia) is potentially fatal
Emergency Response
Call emergency services immediately for: seizures, chest pain, loss of consciousness, breathing difficulty, confusion, extreme agitation, or irregular heartbeat. Tell responders the substance category (synthetic cannabinoid) even without specific identification — this guides appropriate supportive treatment.
Testing Limitations
No field reagent reliably identifies synthetic cannabinoids from a smoking mixture. Laboratory GC-MS or LC-MS testing is required for identification. This means field testing does not provide the safety assurance it provides for other substances.
Toxicity & Safety
Life-Threatening Toxicity
AB-FUBINACA and other indazolecarboxamide synthetic cannabinoids have caused confirmed fatalities and numerous near-fatal events. The toxicity profile differs qualitatively from cannabis intoxication:
Cardiovascular: Tachycardia, bradycardia, chest pain, ST-segment changes, myocardial infarction, and cardiac arrest have been documented. Young, otherwise healthy users have experienced cardiac events attributed directly to AB-FUBINACA toxicity.
Neurological: Seizures, status epilepticus, loss of consciousness, and coma. Acute psychotic episodes with agitation, paranoia, and violence that may persist beyond acute intoxication.
Renal: Acute kidney injury and renal failure — a toxicity not associated with THC and believed to reflect off-target effects of synthetic cannabinoid metabolites.
Respiratory: Respiratory depression and aspiration pneumonia in severe toxicity.
Mass Poisoning Events
AB-FUBINACA was responsible for a documented mass poisoning event in New York City in 2016, when 33 people were hospitalized in a single day from use of synthetic cannabinoid products containing it. This event is cited in public health literature as a case study in the mass-casualty potential of potent synthetic cannabinoids.
No Antidote
There is no specific pharmacological antidote for synthetic cannabinoid toxicity. Treatment is supportive. Cannabis-derived CBD or THC may theoretically modulate CB1 signaling but has not been established as effective rescue treatment.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
overdose will cause physical discomfort including heart palpitations, vertigo and sedation at much lower than dangerous doses, usually causing the user to suffer large amounts of anxiety or to fall asleep.
It is worth noting that this compound has been linked to multiple hospitalizations and deaths due to its use.
It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase one's current state of mind and emotions. Also, like THC, prolonged usage of synthetic cannabinoids may increase one's disposition to mental illness and psychosis, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).
As synthetic cannabinoids are active in the milligram range (with below 5mg being a typical dose), it is important to use proper precautions when dosing to avoid a negative experience.
It is strongly recommended that one use harm reduction practices when using this drug.
As with other synthetic cannabinoids, the chronic use of AB-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of AB-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). AB-FUBINACA presents cross-tolerance with Cross-all cannabinoids, meaning that after the consumption of AB-FUBINACA all cannabinoids will have a redu
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Internationally, AB-FUBINACA was added to the UN Convention on Psychotropic Substances as a Schedule II controlled substance in March 2020.
China: As of October 2015 AB-FUBINACA is a controlled substance in China.
Germany: AB-FUBINACA is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: AB-FUBINACA is a Schedule I drug.
Poland: AB-FUBINACA is under the II-P group as of March 11, 2021. It is illegal to own, possess, and sell in Poland.
Switzerland: AB-FUBINACA is a controlled substance specifically named under Verzeichnis E.
United Kingdom: AB-FUBINACA is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016 and is illegal to possess, produce, supply, or import.
United States: In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.
Responsible use
THJ-018
AB-FUBINACA (Wikipedia)
AB-FUBINACA (Isomer Design)
Discussion
AB-FUBINACA (UKCR)
Tips (4)
If using AB-FUBINACA, have a sober person present. Seizures, severe anxiety, and loss of consciousness can occur without warning. The sitter should be prepared to call emergency services and place you in recovery position.
Synthetic cannabinoids like AB-FUBINACA are far more dangerous than natural cannabis. They are full agonists at CB1 receptors, producing much stronger effects with a higher risk of seizures, psychosis, and organ damage.
Consider whether the risk of AB-FUBINACA is worth it compared to natural cannabis where available. Synthetic cannabinoids were created to evade drug tests and laws, not because they are better or safer than cannabis.
Dose AB-FUBINACA extremely conservatively. Synthetic cannabinoids are active at much lower doses than THC and potency varies enormously between batches. A dose that was mild from one batch could be dangerously strong from another.
See Also
References (3)
- PubChem: AB-FUBINACA
PubChem compound page for AB-FUBINACA (CID: 58124325)
pubchem - AB-FUBINACA - TripSit Factsheet
TripSit factsheet for AB-FUBINACA
tripsit - AB-FUBINACA - Wikipedia
Wikipedia article on AB-FUBINACA
wikipedia